Effects of breviscapine on amyloid beta 1-42 induced Alzheimer's disease mice: A HPLC-QTOF-MS based plasma metabonomics study

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 1057, Issue , 2017, Pages 92-100

  Xia, Hongjun ^a   Wu, Lingling ^a   Chu, Mengying ^a   Feng, Huimin ^a   Lu, Chunliang ^a   Wang, Qinghe ^b   He, Minghai ^b   Ge, Xiaoqun ^a  

^a YANGZHOU UNIVERSITY   (China)

^b Bruker Corporation   (United States)

Author keywords

Alzheimer's disease; Amyloid beta 1 42; Breviscapine; HPLC QTOF MS; Metabonomics; Mice

Indexed keywords

GLYCOPROTEINS; MAMMALS; METABOLISM; MULTIVARIANT ANALYSIS; PHOSPHOLIPIDS;

ALZHEIMER'S DISEASE; AMYLOID BETAS; BREVISCAPINE; HPLC-QTOF-MS; METABONOMICS; MICE;

NEURODEGENERATIVE DISEASES;

ACETYLCHOLINE; ACYLTRANSFERASE; AMYLOID BETA PROTEIN[1-42]; BREVISCAPINE; CHOLESTEROL; DONEPEZIL; INDOLEACRYLIC ACID; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHOLIPASE; LYSOPHOSPHOLIPID; NEUROTRANSMITTER; PHOSPHATIDIC ACID; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE A2; PHOSPHOLIPID; SEROTONIN; SPHINGANINE; SULFOLITHOCHOLIC ACID; TAURODEOXYCHOLIC ACID; TRYPTOPHAN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BIOLOGICAL MARKER; FLAVONOID; NEUROPROTECTIVE AGENT; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LEARNING DISORDER; LIPID METABOLISM; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN METABOLISM; TIME OF FLIGHT MASS SPECTROMETRY; ULTRA HIGH RESOLUTION QUADRUPOLE TIME OF FLIGHT TANDEM MASS SPECTROMETRY; ANIMAL; ANIMAL BEHAVIOR; BLOOD; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; INSTITUTE FOR CANCER RESEARCH MOUSE; MAZE TEST; METABOLISM; METABOLOMICS; PROCEDURES; PSYCHOLOGY; TANDEM MASS SPECTROMETRY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BEHAVIOR, ANIMAL; BIOMARKERS; CHOLESTEROL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; FLAVONOIDS; MALE; MAZE LEARNING; METABOLIC NETWORKS AND PATHWAYS; METABOLOMICS; MICE; MICE, INBRED ICR; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PHOSPHOLIPIDS; SEROTONIN; TANDEM MASS SPECTROMETRY; TRYPTOPHAN;

EID: 85019112434     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2017.05.003     Document Type: Article

References (49)

1. [1] Chinese Pharmacopiea 2015 Edition, vol. I, 2015, China Medical Science Press.
2. [2] Zhu, J.T., Choi, R.C., Li, J., Xie, H.Q., Bi, C.W., Cheung, A.W., Dong, T.T., Jiang, Z.Y., Chen, J.J., Tsim, K.W., Estrogenic and neuroprotective properties of scutellarin from Erigeron breviscapus: a drug against postmenopausal symptoms and Alzheimer's disease. Planta Med. 75 (2009), 1489–1493.
3. [3] Hardy, J., Selkoe, D.J., The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002), 353–356.
4. [4] Frozza, R.L., Bernardi, A., Hoppe, J.B., Meneghetti, A.B., Matté, A., Battastini, A.M., Pohlmann, A.R., Guterres, S.S., Salbego, C., Neuroprotective effects of resveratrol against Aβ administration in rats are improved by lipid-core nanocapsules. Mol. Neurobiol. 47 (2013), 1066–1080.
5. (1-42)-mediated neurotoxicity by regulating calcium homeostasis and ameliorating oxidative stress in hippocampus of rats. J. Neurol. Sci. 280 (2009), 71–78.
6. 1-40 and alleviates astrogliosis in the hippocampus of rats. Brain Res. 1429 (2012), 145–154.
7. 25–35-induced learning and memory impairments in mice. Psychopharmacology (Berl) 219 (2012), 181–190.
8. [8] Diaz, A., Limon, D., Chávez, R., Zenteno, E., Guevara, J., Aβ25-35 injection into the temporal cortex induces chronic inflammation that contributes to neurodegeneration and spatial memory impairment in rats. J. Alzheimers Dis. 30 (2012), 505–522.
9. [9] Lalande, J., Halley, H., Balayssac, S., Gilard, V., Déjean, S., Martino, R., Francés, B., Lassalle, J.M., Malet-Martino, M., 1H NMR metabolomic signatures in five brain regions of the AβPPswe Tg2576 mouse model of Alzheimer's disease at four ages. J. Alzheimers Dis. 39 (2014), 121–143.
10. [10] Salek, R.M., Xia, J., Innes, A., Sweatman, B.C., Adalbert, R., Randle, S., McGowan, E., Emson, P.C., Griffin, J.L., A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochem. Int. 56 (2010), 937–947.
11. [11] Tang, Z., Liu, L.F., Li, Y.L., Dong, J.Y., Li, M., Huang, J.D., Lin, S.H., Cai, Z.W., Urinary metabolomics reveals alterations of aromatic amino acid metabolism of Alzheimer's disease in the transgenic CRND8 mice. Curr. Alzheimer Res. 13 (2016), 764–776.
12. [12] Hu, Z.P., Browne, E.R., Liu, T., Angel, T.E., Ho, P.C., Chan, E.C., Metabonomic profiling of TASTPM transgenic Alzheimer's disease mouse model. J. Proteome Res. 11 (2012), 5903–5913.
13. [13] Wu, J.F., Fu, B., Lei, H.H., Tang, H.R., Wang, Y.L., Gender differences of peripheral plasma and liver metabolic profiling in APP/PS1 transgenic AD mice. Neuroscience 332 (2016), 160–169.
14. [14] Wang, G., Zhou, Y., Huang, F.J., Tang, H.D., Xu, X.H., Liu, J.J., Wang, Y., Deng, Y.L., Ren, R.J., Xu, W., Ma, J.F., Zhang, Y.N., Zhao, A.H., Chen, S.D., Jia, W., Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment. J. Proteome Res. 13 (2014), 2649–2658.
15. [15] Li, N.J., Liu, W.T., Li, W., Li, S.Q., Chen, X.H., Bi, K.S., He, P., Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry. Clin. Biochem. 43 (2010), 992–997.
16. [16] Tukiainen, T., Tynkkynen, T., Mäkinen, V.P., Jylänki, P., Kangas, A., Hokkanen, J., Vehtari, A., Gröhn, O., Hallikainen, M., Soininen, H., Kivipelto, M., Groop, P.H., Kaski, K., Laatikainen, R., Soininen, P., Pirttilä, T., Ala-Korpela, M., A multi-metabolite analysis of serum by 1H NMR spectroscopy: early systemic signs of Alzheimer's disease. Biochem. Biophys. Res. Commun. 375 (2008), 356–361.
17. [17] Czech, C., Berndt, P., Busch, K., Schmitz, O., Wiemer, J., Most, V., Hampel, H., Kastler, J., Senn, H., Metabolite profiling of Alzheimer's disease cerebrospinal fluid. PLoS One, 7, 2012, e31501.
18. [18] Ibáñez, C., Simó, C., Martín-Álvarez, P.J., Kivipelto, M., Winblad, B., Cedazo-Mínguez, A., Cifuentes, A., Toward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass spectrometry metabolomics. Anal. Chem. 84 (2012), 8532–8540.
19. [19] Graham, S.F., Chevallier, O.P., Roberts, D., Hölscher, C., Elliott, C.T., Green, B.D., Investigation of the human brain metabolome to identify potential markers for early diagnosis and therapeutic targets of Alzheimer's disease. Anal. Chem. 85 (2013), 1803–1811.
20. [20] González-Domínguez, R., García-Barrera, T., Vitorica, J., Gómez-Ariza, J.L., High throughput multiorgan metabolomics in the APP/PS1 mouse model of Alzheimer's disease. Electrophoresis 36 (2015), 2237–2249.
21. [21] Greenberg, N., Grassano, A., Thambisetty, M., Lovestone, S., Legido-Quigley, C., A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Electrophoresis 30 (2009), 1235–1239.
22. [22] Chu, H., Zhang, A.H., Han, Y., Lu, S.W., Kong, L., Han, J.W., Liu, Z.D., Sun, H., Wang, X.J., Metabolomics approach to explore the effects of Kai-Xin-San on Alzheimer's disease using UPLC/ESI-Q-TOF mass spectrometry. J. Chromatogr. B 1015:1016 (2016), 50–61.
23. [23] Gong, Y.G., Liu, Y., Zhou, L., Di, X., Li, W., Li, Q., Bi, K.S., A UHPLC-TOF/MS method based metabonomic study of total ginsenosides effects on Alzheimer disease mouse model. J. Pharm. Biomed. Anal. 115 (2015), 174–182.
24. [24] Paxinos, G., Franklin, K.B.J., The Mouse Brain in Stereotaxic Coorinates. second ed., 2001, Academic Press.
25. [25] Bijlsma, S., Bobeldijk, I., Verheij, E.R., Ramaker, R., Kochhar, S., Macdonald, I.A., van Ommen, B., Smilde, A.K., Large-scale human metabolomics studies: a strategy for data (Pre-) processing and validation. Anal. Chem. 78 (2006), 567–574.
26. [26] Vestergaard, M.C., Morita, M., Hamada, T., Takagi, M., Membrane fusion and vesicular transformation induced by Alzheimer's amyloid beta. Biochim. Biophys. Acta 1828 (2013), 1314–1321.
27. 1-42 peptide: role of oligomer formation. Neuroscience 292 (2015), 159–169.
28. [28] Orešič, M., Hyötyläinen, T., Herukka, S.K., Sysi-Aho, M., Mattila, I., Seppänan-Laakso, T., Julkunen, V., Gopalacharyulu, P.V., Hallikainen, M., Koikkalainen, J., Kivipelto, M., Helisalmi, S., Lötjönen, J., Soininen, H., Metabolome in progression to Alzheimer's disease. Transl. Psychiatry, 1, 2011, e57.
29. [29] Tajima, Y., Ishikawa, M., Maekawa, K., Murayama, M., Senoo, Y., Nishimaki-Mogami, T., Nakanishi, H., Ikeda, K., Arita, M., Taguchi, R., Okuno, A., Mikawa, R., Niida, S., Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer's disease. Lipids Health Dis., 12, 2013, 68.
30. [30] Chan, R.B., Oliveira, T.G., Cortes, E.P., Honig, L.S., Duff, K.E., Small, S.A., Wenk, M.R., Shui, G.H., Paolo, G.D., Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J. Biol. Chem. 287 (2012), 2678–2688.
31. [31] González-Domínguez, R., García-Barrera, T., Gómez-Ariza, J.L., Combination of metabolomic and phospholipid-profiling approaches for the study of Alzheimer's disease. J. Proteomics 104 (2014), 37–47.
32. [32] Li, N.J., Liu, Y., Li, W., Zhou, L., Li, Q., Wang, X.Q., He, P., A UPLC/MS-based metabolomics investigation of the protective effect of ginsenosides Rg1 and Rg2 in mice with Alzheimer's disease. J. Ginseng Res. 40 (2016), 9–17.
33. [33] Whiley, L., Sen, A., Heaton, J., Proitsi, P., García-Gómez, D., Leung, R., Smith, N., Thambisetty, M., Kloszewska, I., Mecocci, P., Soininen, H., Tsolaki, M., Vellas, B., Lovestone, S., Legido-Quigley, C., Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol. Aging 35 (2014), 271–278.
34. [34] Grimm, M.O., Grösgen, S., Riemenschneider, M., Tanila, H., Grimm, H.S., Hartmann, T., From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry. J. Chromatogr. A 1218 (2011), 7713–7722.
35. [35] Mulder, C., Wahlund, L.O., Teerlink, T., Blomberg, M., Veerhuis, R., van Kamp, G.J., Scheltens, P., Scheffer, P.G., Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer's disease. J. Neural Transm. (Vienna) 110 (2003), 949–955.
36. 2. Biochim. Biophys. Acta 1778 (2008), 2512–2519.
37. [37] Gella, A., Durany, N., Oxidative stress in Alzheimer disease. Cell Adh. Migr. 3 (2009), 88–93.
38. [38] Klein, J., Membrane breakdown in acute and chronic neurodegeneration: focus on choline-containing phospholipids. J. Neural Transm. (Vienna) 107 (2000), 1027–1063.
39. 2 activity. J. Neurochem. 70 (1998), 786–793.
40. [40] Farooqui, A.A., Liss, L., Horrocks, L.A., Elevated activities of lipases and lysophospholipase in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 1 (1990), 208–214.
41. [41] Weng, R., Shen, S.S., Yang, L., Li, M., Tian, Y.L., Bai, Y., Liu, H.W., Lipidomic analysis of p-chlorophenylalanine-treated mice using continuous-flow two-dimensional liquid chromatography/quadrupole time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 29 (2015), 1491–1500.
42. [42] Noristani, H.N., Verkhratsky, A., Rodríguez, J.J., High tryptophan diet reduces CA1 intraneuronal β-amyloid in the triple transgenic mouse model of Alzheimer's disease. Aging Cell 11 (2012), 810–822.
43. [43] Umeda, T., Tomiyama, T., Kitajima, E., Idomoto, T., Nomura, S., Lambert, M.P., Klein, W.L., Mori, H., Hypercholesterolemia accelerates intraneuronal accumulation of Aβ oligomers resulting in memory impairment in Alzheimer's disease model mice. Life Sci. 91 (2012), 1169–1176.
44. [44] Refolo, L.M., Pappolla, M.A., Malester, B., LaFrancois, J., Bryant-Thomas, T., Wang, R., Tint, G.S., Sambamurti, K., Duff, K.E., Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7 (2000), 321–331.
45. [45] Fassbender, K., Simons, M., Bergmann, C., Stroick, M., Lütjohann, D., Keller, P., Runz, H., Kühl, S., Bertsch, T., von Bergmann, K., Hennerici, M., Beyreuther, K., Hartmann, T., Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. PNAS 98 (2001), 5856–5861.
46. [46] Refolo, L.M., Pappolla, M.A., LaFrancois, J., Malester, B., Schmidt, S.D., Bryant-Thomas, T., Tint, G.S., Wang, R., Mercken, M., Petanceska, S.S., Duff, K.E., A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8 (2001), 890–899.
47. [47] Li, Q., Wu, J.H., Guo, D.J., Cheng, H.L., Chen, S.L., Chan, S.W., Suppression of diet-induced hypercholesterolemia by scutellarin in rats. Planta Med. 75 (2009), 1203–1208.
48. [48] Xia, H.J., Qiu, F., Zhu, S., Zhang, T.Y., Qu, G.X., Yao, X.S., Isolation and identification of ten metabolites of breviscapine in rat urine. Biol. Pharm. Bull. 30 (2007), 1308–1316.
49. [49] Wang, X., Xia, H.J., Liu, Y.P., Qiu, F., Di, X., Simultaneous determination of three glucuronide conjugates of scutellarein in rat plasma by LC–MS/MS for pharmacokinetic study of breviscapine. J. Chromatogr. B 965 (2014), 79–84.